Login to Your Account



'No Surprise': Genentech, OSI Report Tarceva Phase III Miss

By Kim Coghill


Thursday, October 2, 2003
When AstraZeneca plc's Iressa failed to improve survival in non-small-cell lung cancer patients as a treatment added to first-line standards of care, executives at Genentech Inc. and partners OSI Pharmaceuticals Inc. and Roche Holdings Inc. got some less-than-inspiring insight into the possible future of Tarceva, a candidate the three have been studying in a similar population. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription